{"id":38248,"date":"2020-06-26T07:32:29","date_gmt":"2020-06-26T07:32:29","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=38248"},"modified":"2020-06-26T09:50:46","modified_gmt":"2020-06-26T09:50:46","slug":"modeling-paper-suggests-hydroxychloroquine-dosing-was-too-low-to-be-active-against-covid-19-and-that-higher-doses-would-risk-toxicity","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/38248","title":{"rendered":"Modelling paper suggests hydroxychloroquine dosing was too low to be active against COVID-19 and that higher doses would risk toxicity"},"content":{"rendered":"<p class=\"HTBBODYtext\"><strong><b><span lang=\"EN-US\"><img loading=\"lazy\" decoding=\"async\" class=\" alignright\" src=\"https:\/\/i-base.info\/wp-content\/uploads\/2020\/03\/COVID-19-graphic.png\" width=\"231\" height=\"142\" \/><\/span><\/b>Simon Collins, HIV i-Base<\/strong><\/p>\n<p class=\"HTBBODYtext\"><strong><span lang=\"EN-US\">A paper published on 21 May 2020 in Clinical Infectious Diseases by Fan and colleagues, modelled drug levels of hydroxychloroquine (HCQ) in vitro to show that dosing for human studies was unlikely to be effective. [1]<\/span><\/strong><\/p>\n<p class=\"HTBBODYtext\">It suggests that <span lang=\"EN-US\">in vitro EC50\/EC90 values for HCQ should be compared to the in vivo free extracellular tissue concentration (which is similar to the free plasma HCQ concentration). <\/span><\/p>\n<p class=\"HTBBODYtext\">It also concludes that none of the current studies using HCQ as treatment for COVID-19 are\/were using a high enough dose to expect to see a significant clinical effect and that dosing any higher would lead to unacceptable toxicity.<\/p>\n<p class=\"HTBBODYtext\">The range of ongoing studies registered to use hydroxychloroquine to treat or prevent COVID-19 already shows wide difference on the most appropriate dose. At least one study was stopped early due to excessing overdosing and serious side effects. [2]<\/p>\n<p class=\"HTBBODYtext\">Many other studies have reported no benefit. This includes the UK RECOVERY study, closing this arm of the study and contributing to the International WHO SOLIDARITY study also discontinuing HCQ. [2, 3, 4]<\/p>\n<p class=\"HTBBODYtext\"><span lang=\"EN-US\">This paper modelling dosing suggests that activity against CoV-2 is unlikely at any of the current doses and that higher doses needed for activity would increase the risk toxicity.<\/span><\/p>\n<p class=\"HTBBODYtext\"><span lang=\"EN-US\">An excellent editorial article by Charles Flexner et al in Clinical Infectious Diseases further explains the complex pharmacokinetics of HCQ and the problems of dosing for different indications. [6]<\/span><\/p>\n<p class=\"HTBBODYtext\"><span lang=\"EN-US\">This was included in reference to two papers in the same journal using contradictory approaches to study design. [7, 8]<\/span><\/p>\n<p class=\"HTBreferences\"><span lang=\"EN-US\"><em>This article was first published online on 23 June 2020.<\/em><\/span><\/p>\n<p class=\"HTBreferences\"><span lang=\"EN-US\">References<\/span><\/p>\n<ol>\n<li class=\"HTBreferences\"><span lang=\"EN-US\">Fan J et al. Connecting hydroxychloroquine in vitro antiviral activity to in vivo concentration for prediction of antiviral effect: a critical step in treating COVID-19 patients.\u00a0<\/span>Clinical Infectious Diseases, ciaa623. DOI:\u00a010.1093\/cid\/ciaa623. (21 May 2020).<br \/>\n<a href=\"https:\/\/academic.oup.com\/cid\/advance-article\/doi\/10.1093\/cid\/ciaa623\/5841401\" rel=\"noopener noreferrer\">https:\/\/academic.oup.com\/cid\/advance-article\/doi\/10.1093\/cid\/ciaa623\/5841401<\/a><\/li>\n<li class=\"HTBreferences\">High-dose chloroquine study for COVID-19 stopped with worse outcomes: high risk of cardiovascular events. HIV and COVID-19, HTB. (17 April 2020).<br \/>\n<a href=\"https:\/\/i-base.info\/htb\/37691\" rel=\"noopener noreferrer\">https:\/\/i-base.info\/htb\/37691<\/a><\/li>\n<li class=\"HTBreferences\">Studies reporting lack of benefit from hydroxychloroquine to treat COVID-19. HIV and COVID-19, HTB. (14 May 2020).<br \/>\n<a href=\"https:\/\/i-base.info\/htb\/37803\" rel=\"noopener noreferrer\">https:\/\/i-base.info\/htb\/37803<\/a><\/li>\n<li class=\"HTBreferences\">Collins S. UK RECOVERY study stops hydroxychloroquine (HCQ) for COVID-19: more than 1100 deaths question ethics and safety overall. HTB early access (6 June 2020).<br \/>\n<a href=\"https:\/\/i-base.info\/htb\/38188\" rel=\"noopener noreferrer\">https:\/\/i-base.info\/htb\/38188<\/a><\/li>\n<li class=\"HTBreferences\">WHO. \u201cSolidarity\u201d clinical trial for COVID-19 treatments. Update on hydroxychloroquine. (17 June 2020). <a href=\"https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/global-research-on-novel-coronavirus-2019-ncov\/solidarity-clinical-trial-for-covid-19-treatments\" rel=\"noopener noreferrer\">https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/global-research-on-novel-coronavirus-2019-ncov\/solidarity-clinical-trial-for-covid-19-treatments<\/a><\/li>\n<li class=\"HTBreferences\">Flexner C et al. Dose optimization of hydroxychloroquine for COVID-19: do blood concentrations matter?\u00a0Clinical Infectious Diseases, ciaa691. DOI: 10.1093\/cid\/ciaa691. (31 May 2020).<br \/>\n<a href=\"https:\/\/academic.oup.com\/cid\/advance-article\/doi\/10.1093\/cid\/ciaa691\/5849325\" rel=\"noopener noreferrer\">https:\/\/academic.oup.com\/cid\/advance-article\/doi\/10.1093\/cid\/ciaa691\/5849325<\/a><\/li>\n<li class=\"HTBreferences\">Martin-Blondel G et al. Hydroxychloroquine in COVID-19 patients: what still needs to be known about the kinetics. Clin Infect Dis 2020. [Epub ahead of print]<br \/>\n<a href=\"https:\/\/academic.oup.com\/cid\/advance-article\/doi\/10.1093\/cid\/ciaa558\/5835847\" rel=\"noopener noreferrer\">https:\/\/academic.oup.com\/cid\/advance-article\/doi\/10.1093\/cid\/ciaa558\/5835847<\/a><\/li>\n<li class=\"HTBreferences\">Perinel S et al. Towards optimization of hydroxychloroquine dosing in intensive care unit COVID-19 patients. Clin Infect Dis 2020. [Epub ahead of print]<br \/>\n<a href=\"https:\/\/academic.oup.com\/cid\/advance-article\/doi\/10.1093\/cid\/ciaa394\/5816960\" rel=\"noopener noreferrer\">https:\/\/academic.oup.com\/cid\/advance-article\/doi\/10.1093\/cid\/ciaa394\/5816960<\/a>\n<p class=\"HTBreferences\"><span lang=\"EN-US\">\u00a0<\/span><\/p>\n<p class=\"HTBreferences\"><span lang=\"EN-US\">\u00a0<\/span><\/p>\n<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Simon Collins, HIV i-Base A paper published on 21 May 2020 in Clinical Infectious Diseases by Fan and colleagues, modelled drug levels of hydroxychloroquine (HCQ) in vitro to show that dosing for human studies was unlikely to be effective. [1] &hellip;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[283,278],"tags":[],"class_list":["post-38248","post","type-post","status-publish","format-standard","hentry","category-covid-19-investigational-drugs","category-covid-19"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/38248","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=38248"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/38248\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=38248"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=38248"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=38248"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}